Announcements
- Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
- Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
- Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer
- Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
- Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
- Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules
- Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
- Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
More ▼
Key statistics
On Friday, Cyclacel Pharmaceuticals Inc (CYCCP:NAQ) closed at 8.11, 54.48% above the 52 week low of 5.25 set on Nov 08, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.52 |
---|---|
High | 8.80 |
Low | 8.11 |
Bid | 7.50 |
Offer | -- |
Previous close | 9.41 |
Average volume | 7.03k |
---|---|
Shares outstanding | 1.46m |
Free float | 1.36m |
P/E (TTM) | -- |
Market cap | 2.36m USD |
EPS (TTM) | -21.99 USD |
Annual div (ADY) | -- |
---|---|
Annual div yield (ADY) | -- |
Div ex-date | Jan 19 2024 |
Div pay-date | Feb 01 2024 |
Data delayed at least 15 minutes, as of Jul 05 2024 20:54 BST.
More ▼